Good to see that the scientific progress continues on a steady course.

One the struck me in the release is... "Under the terms of the agreement, Hepalink is responsible for certain clinical and development costs in the Territories, for a Taiwan/China patient population that is now being included in Resverlogix's Phase 3 BETonMACE trial. As a result of the randomization, Hepalink is now responsible for the first CAD$1 million payment to Resverlogix".

I know I had seen that in the original agreement and it seems to say that this will be the first income that RVX has ever made? Am I right?

Either way, it is good news to finally hear something about this.

GLTA

Toinv